A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan.

MLA

Horigome, Yuichi, et al. “A Prospective, Multicenter, Observational Study of Ixazomib plus Lenalidomide-Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma in Japan.” Annals of Hematology, vol. 103, no. 2, Feb. 2024, pp. 475–88. EBSCOhost, https://doi.org/10.1007/s00277-023-05428-7.

APA

Horigome, Y., Iino, M., Harazaki, Y., Kobayashi, T., Handa, H., Hiramatsu, Y., Kuroi, T., Tanimoto, K., Matsue, K., Abe, M., Ishida, T., Ito, S., Iwasaki, H., Kuroda, J., Shibayama, H., Sunami, K., Takamatsu, H., Tamura, H., Hayashi, T., & Akagi, K. (2024). A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan. Annals of Hematology, 103(2), 475–488. https://doi.org/10.1007/s00277-023-05428-7

Chicago

Horigome, Yuichi, Masaki Iino, Yoriko Harazaki, Takahiro Kobayashi, Hiroshi Handa, Yasushi Hiramatsu, Taiga Kuroi, et al. 2024. “A Prospective, Multicenter, Observational Study of Ixazomib plus Lenalidomide-Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma in Japan.” Annals of Hematology 103 (2): 475–88. doi:10.1007/s00277-023-05428-7.